April 10, 2020 -- Clinical-stage biopharmaceutical company TFF Pharmaceuticals has partnered with researchers at the University of Georgia and University of Texas (UT) to evaluate universal influenza vaccines.
Through the collaboration, researchers at UT Austin will formulate hemagglutinin and neuraminidase proteins using TFF's thin-film freezing technology. Then, researchers at the University of Georgia's Center for Vaccines and Immunology will evaluate the immune responses to the compounds.
The research resulting from the collaboration could lead to a vaccine that protects people against multiple forms of influenza, including seasonal and pandemic flus.